MB
Marco Boorsma
General Partner at Forbion
MB
Marco Boorsma
General Partner at Forbion
Amsterdam Area
Overview
Work Experience
General Partner
2017 - Current
Partner
2014 - 2017
Principal
2010 - 2014
Senior Analyst
2007 - 2010
Board Director at Calluna Pharma
2024
Board Director at Sitala
2021
Board Director at Rectify Pharma
2021
Board Director at VectorY
2021
VectorY develops innovative vectorized antibody gene therapies
Chief Executive Officer
2020 - 2021
VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
Chairman of the Board
2020 - 2023
Oxitope Pharma was merged with Arxx Therapeutics into Calluna Pharma
Board Director at enGene
2017 - 2023
EnGene (Nasdaq: ENGN) develops non-viral gene therapies targeting mucosal tissues. Lead program is in pivotal clinical studies in NMIBC
Board Director at Inversago
2020 - 2023
Inversago develops peripherally acting CB1 inhibitors for treatment of metabolic and inflammatory diseases. Inversago was acquired by Novo Nordisk
Board Director at Escalier Biosciences
2018 - 2023
Escalier develops novel therapeutics to treat autoimmune diseases
Board Director at Inflazome
2018 - 2020
Inflazome was acquired by Roche